A Randomized Double-Blind Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Afatinib (BIBW 2992) as Adjuvant Therapy after Chemo-Radiotherapy in Primary Unresected Patients with Stage III IVa or IVb Loco-Regionally Advanced He
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this research study is to test the safety and ability of the study drug, afatinib, compared to placebo to extend the length of time a subject remains cancer free.
Description
The purpose of this research study is to test the safety and ability of the study drug, afatinib, compared to placebo to extend the length of time a subject remains cancer free.
Details
| Condition | Squamous Cell Cancer (Head and Neck) |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX2460 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.